Novan Therapeutics’s Nitricil™ Technology Shows Efficacy Against Multidrug Resistant Superbugs

DURHAM, N.C.--(BUSINESS WIRE)--Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced today that the Company’s Nitricil™ platform technology has been shown to be efficacious against several of the most multi-drug resistant pathogens plaguing civilian and military health care providers across the globe. The antimicrobial results from two preclinical studies will be presented this evening at the 2014 Military Health System Research Symposium (MHSRS), taking place in Fort Lauderdale, Florida. Among key findings, Novan’s nitric oxide-releasing technology was shown to be effective against Acinetobacter baumannii, a gram-negative bacterium resistant to nearly all antibiotics, including carbapenems (often considered antibiotics of last resort). A. baumannii causes pneumonia, urinary tract infection, and combat- and trauma-related wound infections.

Help employers find you! Check out all the jobs and post your resume.